Stroke is still a leading cause of death all over the world. A new AI model showed early potential to anticipate such adverse outcomes up to a decade in advance, ensuring high-risk patients receive the care they need.
The Shockwave C2 Aero Coronary IVL Catheter is based on years of user feedback. For example, it was built with improved deliverability and repositioning capabilities in mind.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
When CMS finalized coverage for cardiac ablations performed in ASCs, experts from HRS and ACC published recommendations for performing those procedures safely and effectively. One of the cardiologists behind that guidance shared some important takeaways with Cardiovascular Business.
Follow-up care after a successful heart transplant can be challenging—both for providers and their patients. Consider, for example, the fact that so many patients who develop complications never actually present with symptoms.
“Radiologists are well-positioned to contribute evidence-based guidance, promote transparency, and help patients make informed decisions," experts write in Clinical Imaging.
Epic makes the list with its enterprise inpatient EHR and related platforms. So does PCC, aka Physician’s Computer Company, which supplies pediatric-specific ambulatory EHR and practice-management products and services.
Experts agree that most patients younger than 65 should be treated with surgery instead of TAVR. According to a new real-world analysis, however, more and more of these patients are undergoing TAVR.
Stroke is still a leading cause of death all over the world. A new AI model showed early potential to anticipate such adverse outcomes up to a decade in advance, ensuring high-risk patients receive the care they need.
The Shockwave C2 Aero Coronary IVL Catheter is based on years of user feedback. For example, it was built with improved deliverability and repositioning capabilities in mind.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
